Personalized Neuropsychiatric Treatment and Risk Assessment Platform

A next-generation platform integrating genomics, machine learning, and wearable technology to revolutionize neuropsychiatric diagnosis, treatment, and prevention.

The original patent disclosed systems and methods for screening, diagnosing, and stratifying patients with neuropsychiatric diseases. However, these methods relied on traditional Bayesian decision lists and lacked the precision and personalization offered by modern genomics and machine learning. The new inventive concept addresses this limitation by leveraging cutting-edge technologies to provide more accurate and effective treatment plans.

The platform consists of four interconnected components: (1) a neural network trained on genomic data and patient outcomes, predicting optimal treatment regimens; (2) a machine learning algorithm analyzing genomic data and medical history to generate a neuropsychiatric disease risk score; (3) a wearable device tracking physiological and behavioral responses to treatment, with a cloud-based analytics platform adapting the treatment plan accordingly; and (4) a graph-based machine learning algorithm identifying novel therapeutic targets for neuropsychiatric diseases. These components enable personalized treatment planning, real-time monitoring, and adaptation of treatment plans.

The new claims introduce a paradigm shift in neuropsychiatric diagnosis and treatment by integrating genomics, machine learning, and wearable technology. The inventive concept's novelty lies in its ability to provide personalized treatment plans based on unique genomic profiles, predict disease risk scores, and adapt treatment plans in real-time.

Alternative embodiments may include the use of different machine learning algorithms, integration with electronic health records, or incorporation of additional data sources such as environmental or lifestyle factors. Variations may also include the development of specialized platforms for specific neuropsychiatric diseases or the creation of a decentralized platform for secure data sharing and collaboration.

The personalized neuropsychiatric treatment and risk assessment platform has vast commercial potential in the healthcare industry, particularly in the fields of precision medicine, digital therapeutics, and genomic research. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to improve patient outcomes and reduce treatment costs.